Elixiron Immunotherapeutics is driven by a multi-cultural, international team in Shanghai, Taipei, the USA (San Francisco) and Switzerland (Lausanne) with a shared vision to build a global company that brings next-generation immunotherapies to patients in need. This vision drives our mission to target rare and immunological diseases as well as cancer for indications that could substantially benefit from advances in immunotherapy approaches. We employ advances in translational medicine to identify targets from clinical observations, and various drug modalities including biologics derived from a proprietary human antibody domain phage display library and a single human B cell antibody cloning platform to develop innovative therapies. Our two lead pipeline candidates are in phase 1 clinical trials. EI-1071, a small molecule inhibitor of CSF-1R kinase activity, is being explored as a potential therapy for Alzheimer's disease as well as tenosynovial giant cell tumors, and a monoclonal antibody, EI-001 is being developed for the treatment of vitiligo and other immunological disorders.
View Top Employees from Elixiron ImmunotherapeuticsWebsite | http://www.elixiron.com |
Employees | 19 (18 on RocketReach) |
Founded | 2017 |
Technologies |
JavaScript,
HTML,
ASP.NET
+4 more
(view full list)
|
Industry | Biotechnology Research |
Looking for a particular Elixiron Immunotherapeutics employee's phone or email?
Hung-Kai Chen is the Chairman and Chief Executive Officer of Elixiron Immunotherapeutics.
18 people are employed at Elixiron Immunotherapeutics.